Filing Details
- Accession Number:
- 0001209191-23-054914
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-13 07:00:07
- Reporting Period:
- 2023-11-08
- Accepted Time:
- 2023-11-13 07:00:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1095981 | Plus Therapeutics Inc. | PSTV | Surgical & Medical Instruments & Apparatus (3841) | 330827593 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1362635 | P Robert Lenk | C/O Plus Therapeutics Inc. 4200 Marathon Boulevard, Suite 200 Austin TX 78756 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-11-08 | 5,000 | $1.65 | 12,961 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2023-11-09 | 4,199 | $1.59 | 17,160 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.70 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.59 per share. Thereporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, fullinformation regarding the number of shares purchased at each separate price within the range set forth in this footnote.